http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 20 Aug 2026 08:00:40 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Lupin%27s+VISUfarma+licenses+YUVEZZI+eye+drop+for+European+markets/26953180.html <p>Lupin Limited (BSE: 500257, NSE: LUPIN), through its wholly owned subsidiary VISUfarma B.V., has entered into an exclusive licensing agreement with Visus Therapeutics Inc., a subsidiary of Tenpoint Therapeutics Holding Limited, to commercialize YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% across the European Union, the United Kingdom, Switzerland, Norway, and Iceland.</p> <p>Under the agreement, VISUfarma gains exclusive rights to regulatory activities, commercialization, marketing, distribution, and sale of YUVEZZI in the licensed territories. VISUfarma will also make a strategic investment in Visus Therapeutics. Tenpoint and Visus are eligible to receive regulatory and commercial milestone payments, as well as tiered royalties based http://www.streetinsider.com/Corporate+News/Lupin%27s+VISUfarma+licenses+YUVEZZI+eye+drop+for+European+markets/26953180.html Thu, 20 Aug 2026 08:00:40 -0400 500257 A.06822034 A.50202117 A.50216948 LUPIN LUPIN.BO LUPIN.NS O.03319887 O.20026344 O.37382289 O.48334738 http://www.streetinsider.com/Corporate+News/Lupin%27s+VISUfarma+licenses+YUVEZZI+eye+drop+for+European+markets/26953180.html <p>Lupin Limited (BSE: 500257, NSE: LUPIN), through its wholly owned subsidiary VISUfarma B.V., has entered into an exclusive licensing agreement with Visus Therapeutics Inc., a subsidiary of Tenpoint Therapeutics Holding Limited, to commercialize YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% across the European Union, the United Kingdom, Switzerland, Norway, and Iceland.</p> <p>Under the agreement, VISUfarma gains exclusive rights to regulatory activities, commercialization, marketing, distribution, and sale of YUVEZZI in the licensed territories. VISUfarma will also make a strategic investment in Visus Therapeutics. Tenpoint and Visus are eligible to receive regulatory and commercial milestone payments, as well as tiered royalties based http://www.streetinsider.com/Corporate+News/Lupin%27s+VISUfarma+licenses+YUVEZZI+eye+drop+for+European+markets/26953180.html Thu, 20 Aug 2026 08:00:40 -0400 500257 A.06822034 A.50202117 A.50216948 LUPIN LUPIN.BO LUPIN.NS O.03319887 O.20026344 O.37382289 O.48334738 http://www.streetinsider.com/Corporate+News/Lupin%27s+VISUfarma+licenses+YUVEZZI+eye+drop+for+European+markets/26953180.html <p>Lupin Limited (BSE: 500257, NSE: LUPIN), through its wholly owned subsidiary VISUfarma B.V., has entered into an exclusive licensing agreement with Visus Therapeutics Inc., a subsidiary of Tenpoint Therapeutics Holding Limited, to commercialize YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% across the European Union, the United Kingdom, Switzerland, Norway, and Iceland.</p> <p>Under the agreement, VISUfarma gains exclusive rights to regulatory activities, commercialization, marketing, distribution, and sale of YUVEZZI in the licensed territories. VISUfarma will also make a strategic investment in Visus Therapeutics. Tenpoint and Visus are eligible to receive regulatory and commercial milestone payments, as well as tiered royalties based http://www.streetinsider.com/Corporate+News/Lupin%27s+VISUfarma+licenses+YUVEZZI+eye+drop+for+European+markets/26953180.html Thu, 20 Aug 2026 08:00:40 -0400 500257 A.06822034 A.50202117 A.50216948 LUPIN LUPIN.BO LUPIN.NS O.03319887 O.20026344 O.37382289 O.48334738 http://www.streetinsider.com/Corporate+News/Lupin%27s+VISUfarma+licenses+YUVEZZI+eye+drop+for+European+markets/26953180.html <p>Lupin Limited (BSE: 500257, NSE: LUPIN), through its wholly owned subsidiary VISUfarma B.V., has entered into an exclusive licensing agreement with Visus Therapeutics Inc., a subsidiary of Tenpoint Therapeutics Holding Limited, to commercialize YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% across the European Union, the United Kingdom, Switzerland, Norway, and Iceland.</p> <p>Under the agreement, VISUfarma gains exclusive rights to regulatory activities, commercialization, marketing, distribution, and sale of YUVEZZI in the licensed territories. VISUfarma will also make a strategic investment in Visus Therapeutics. Tenpoint and Visus are eligible to receive regulatory and commercial milestone payments, as well as tiered royalties based http://www.streetinsider.com/Corporate+News/Lupin%27s+VISUfarma+licenses+YUVEZZI+eye+drop+for+European+markets/26953180.html Thu, 20 Aug 2026 08:00:40 -0400 500257 A.06822034 A.50202117 A.50216948 LUPIN LUPIN.BO LUPIN.NS O.03319887 O.20026344 O.37382289 O.48334738 http://www.streetinsider.com/Corporate+News/Lupin%27s+VISUfarma+licenses+YUVEZZI+eye+drop+for+European+markets/26953180.html <p>Lupin Limited (BSE: 500257, NSE: LUPIN), through its wholly owned subsidiary VISUfarma B.V., has entered into an exclusive licensing agreement with Visus Therapeutics Inc., a subsidiary of Tenpoint Therapeutics Holding Limited, to commercialize YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% across the European Union, the United Kingdom, Switzerland, Norway, and Iceland.</p> <p>Under the agreement, VISUfarma gains exclusive rights to regulatory activities, commercialization, marketing, distribution, and sale of YUVEZZI in the licensed territories. VISUfarma will also make a strategic investment in Visus Therapeutics. Tenpoint and Visus are eligible to receive regulatory and commercial milestone payments, as well as tiered royalties based http://www.streetinsider.com/Corporate+News/Lupin%27s+VISUfarma+licenses+YUVEZZI+eye+drop+for+European+markets/26953180.html Thu, 20 Aug 2026 08:00:40 -0400 500257 A.06822034 A.50202117 A.50216948 LUPIN LUPIN.BO LUPIN.NS O.03319887 O.20026344 O.37382289 O.48334738 http://www.streetinsider.com/Corporate+News/Lupin%27s+VISUfarma+licenses+YUVEZZI+eye+drop+for+European+markets/26953180.html <p>Lupin Limited (BSE: 500257, NSE: LUPIN), through its wholly owned subsidiary VISUfarma B.V., has entered into an exclusive licensing agreement with Visus Therapeutics Inc., a subsidiary of Tenpoint Therapeutics Holding Limited, to commercialize YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% across the European Union, the United Kingdom, Switzerland, Norway, and Iceland.</p> <p>Under the agreement, VISUfarma gains exclusive rights to regulatory activities, commercialization, marketing, distribution, and sale of YUVEZZI in the licensed territories. VISUfarma will also make a strategic investment in Visus Therapeutics. Tenpoint and Visus are eligible to receive regulatory and commercial milestone payments, as well as tiered royalties based http://www.streetinsider.com/Corporate+News/Lupin%27s+VISUfarma+licenses+YUVEZZI+eye+drop+for+European+markets/26953180.html Thu, 20 Aug 2026 08:00:40 -0400 500257 A.06822034 A.50202117 A.50216948 LUPIN LUPIN.BO LUPIN.NS O.03319887 O.20026344 O.37382289 O.48334738 http://www.streetinsider.com/Corporate+News/Lupin%27s+VISUfarma+licenses+YUVEZZI+eye+drop+for+European+markets/26953180.html <p>Lupin Limited (BSE: 500257, NSE: LUPIN), through its wholly owned subsidiary VISUfarma B.V., has entered into an exclusive licensing agreement with Visus Therapeutics Inc., a subsidiary of Tenpoint Therapeutics Holding Limited, to commercialize YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% across the European Union, the United Kingdom, Switzerland, Norway, and Iceland.</p> <p>Under the agreement, VISUfarma gains exclusive rights to regulatory activities, commercialization, marketing, distribution, and sale of YUVEZZI in the licensed territories. VISUfarma will also make a strategic investment in Visus Therapeutics. Tenpoint and Visus are eligible to receive regulatory and commercial milestone payments, as well as tiered royalties based http://www.streetinsider.com/Corporate+News/Lupin%27s+VISUfarma+licenses+YUVEZZI+eye+drop+for+European+markets/26953180.html Thu, 20 Aug 2026 08:00:40 -0400 500257 A.06822034 A.50202117 A.50216948 LUPIN LUPIN.BO LUPIN.NS O.03319887 O.20026344 O.37382289 O.48334738 http://www.streetinsider.com/Corporate+News/Lupin%27s+VISUfarma+licenses+YUVEZZI+eye+drop+for+European+markets/26953180.html <p>Lupin Limited (BSE: 500257, NSE: LUPIN), through its wholly owned subsidiary VISUfarma B.V., has entered into an exclusive licensing agreement with Visus Therapeutics Inc., a subsidiary of Tenpoint Therapeutics Holding Limited, to commercialize YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% across the European Union, the United Kingdom, Switzerland, Norway, and Iceland.</p> <p>Under the agreement, VISUfarma gains exclusive rights to regulatory activities, commercialization, marketing, distribution, and sale of YUVEZZI in the licensed territories. VISUfarma will also make a strategic investment in Visus Therapeutics. Tenpoint and Visus are eligible to receive regulatory and commercial milestone payments, as well as tiered royalties based http://www.streetinsider.com/Corporate+News/Lupin%27s+VISUfarma+licenses+YUVEZZI+eye+drop+for+European+markets/26953180.html Thu, 20 Aug 2026 08:00:40 -0400 500257 A.06822034 A.50202117 A.50216948 LUPIN LUPIN.BO LUPIN.NS O.03319887 O.20026344 O.37382289 O.48334738 http://www.streetinsider.com/Corporate+News/Lupin%27s+VISUfarma+licenses+YUVEZZI+eye+drop+for+European+markets/26953180.html <p>Lupin Limited (BSE: 500257, NSE: LUPIN), through its wholly owned subsidiary VISUfarma B.V., has entered into an exclusive licensing agreement with Visus Therapeutics Inc., a subsidiary of Tenpoint Therapeutics Holding Limited, to commercialize YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% across the European Union, the United Kingdom, Switzerland, Norway, and Iceland.</p> <p>Under the agreement, VISUfarma gains exclusive rights to regulatory activities, commercialization, marketing, distribution, and sale of YUVEZZI in the licensed territories. VISUfarma will also make a strategic investment in Visus Therapeutics. Tenpoint and Visus are eligible to receive regulatory and commercial milestone payments, as well as tiered royalties based http://www.streetinsider.com/Corporate+News/Lupin%27s+VISUfarma+licenses+YUVEZZI+eye+drop+for+European+markets/26953180.html Thu, 20 Aug 2026 08:00:40 -0400 500257 A.06822034 A.50202117 A.50216948 LUPIN LUPIN.BO LUPIN.NS O.03319887 O.20026344 O.37382289 O.48334738 http://www.streetinsider.com/Corporate+News/Lupin%27s+VISUfarma+licenses+YUVEZZI+eye+drop+for+European+markets/26953180.html <p>Lupin Limited (BSE: 500257, NSE: LUPIN), through its wholly owned subsidiary VISUfarma B.V., has entered into an exclusive licensing agreement with Visus Therapeutics Inc., a subsidiary of Tenpoint Therapeutics Holding Limited, to commercialize YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% across the European Union, the United Kingdom, Switzerland, Norway, and Iceland.</p> <p>Under the agreement, VISUfarma gains exclusive rights to regulatory activities, commercialization, marketing, distribution, and sale of YUVEZZI in the licensed territories. VISUfarma will also make a strategic investment in Visus Therapeutics. Tenpoint and Visus are eligible to receive regulatory and commercial milestone payments, as well as tiered royalties based http://www.streetinsider.com/Corporate+News/Lupin%27s+VISUfarma+licenses+YUVEZZI+eye+drop+for+European+markets/26953180.html Thu, 20 Aug 2026 08:00:40 -0400 500257 A.06822034 A.50202117 A.50216948 LUPIN LUPIN.BO LUPIN.NS O.03319887 O.20026344 O.37382289 O.48334738 http://www.streetinsider.com/Corporate+News/Lupin%27s+VISUfarma+licenses+YUVEZZI+eye+drop+for+European+markets/26953180.html <p>Lupin Limited (BSE: 500257, NSE: LUPIN), through its wholly owned subsidiary VISUfarma B.V., has entered into an exclusive licensing agreement with Visus Therapeutics Inc., a subsidiary of Tenpoint Therapeutics Holding Limited, to commercialize YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% across the European Union, the United Kingdom, Switzerland, Norway, and Iceland.</p> <p>Under the agreement, VISUfarma gains exclusive rights to regulatory activities, commercialization, marketing, distribution, and sale of YUVEZZI in the licensed territories. VISUfarma will also make a strategic investment in Visus Therapeutics. Tenpoint and Visus are eligible to receive regulatory and commercial milestone payments, as well as tiered royalties based http://www.streetinsider.com/Corporate+News/Lupin%27s+VISUfarma+licenses+YUVEZZI+eye+drop+for+European+markets/26953180.html Thu, 20 Aug 2026 08:00:40 -0400 500257 A.06822034 A.50202117 A.50216948 LUPIN LUPIN.BO LUPIN.NS O.03319887 O.20026344 O.37382289 O.48334738 http://www.streetinsider.com/Press+Releases/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html <div class="xn-content"> <p class="prntac"><i>Demonstrates a shared commitment to extend global access for the only once-daily dual-agent presbyopia-correcting eye drop in the rapidly growing presbyopia vision management segment</i></p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location> and <location value="LU/us.nj.warren" idsrc="xmltag.org" >WARREN, New Jersey</location> and <location value="LU/nl..amster" idsrc="xmltag.org" >AMSTERDAM</location> and <location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> ("Lupin") (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that <span>VISUfarma B.V.</span> ("VISUfarma"), a wholly owned subsidiary of Lupin, has entered into an exclusive licensing agreement with <span>Visus Therapeutics Inc., http://www.streetinsider.com/Press+Releases/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html Thu, 20 Aug 2026 08:00:00 -0400 500257 500257 A.06822034 A.50202117 A.50216948 LUPIN LUPIN.BO LUPIN.NS O.03319887 O.20026344 O.37382289 O.48334738 http://www.streetinsider.com/Press+Releases/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html <div class="xn-content"> <p class="prntac"><i>Demonstrates a shared commitment to extend global access for the only once-daily dual-agent presbyopia-correcting eye drop in the rapidly growing presbyopia vision management segment</i></p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location> and <location value="LU/us.nj.warren" idsrc="xmltag.org" >WARREN, New Jersey</location> and <location value="LU/nl..amster" idsrc="xmltag.org" >AMSTERDAM</location> and <location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> ("Lupin") (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that <span>VISUfarma B.V.</span> ("VISUfarma"), a wholly owned subsidiary of Lupin, has entered into an exclusive licensing agreement with <span>Visus Therapeutics Inc., http://www.streetinsider.com/Press+Releases/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html Thu, 20 Aug 2026 08:00:00 -0400 500257 500257 A.06822034 A.50202117 A.50216948 LUPIN LUPIN.BO LUPIN.NS O.03319887 O.20026344 O.37382289 O.48334738 http://www.streetinsider.com/Press+Releases/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html <div class="xn-content"> <p class="prntac"><i>Demonstrates a shared commitment to extend global access for the only once-daily dual-agent presbyopia-correcting eye drop in the rapidly growing presbyopia vision management segment</i></p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location> and <location value="LU/us.nj.warren" idsrc="xmltag.org" >WARREN, New Jersey</location> and <location value="LU/nl..amster" idsrc="xmltag.org" >AMSTERDAM</location> and <location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> ("Lupin") (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that <span>VISUfarma B.V.</span> ("VISUfarma"), a wholly owned subsidiary of Lupin, has entered into an exclusive licensing agreement with <span>Visus Therapeutics Inc., http://www.streetinsider.com/Press+Releases/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html Thu, 20 Aug 2026 08:00:00 -0400 500257 500257 A.06822034 A.50202117 A.50216948 LUPIN LUPIN.BO LUPIN.NS O.03319887 O.20026344 O.37382289 O.48334738 http://www.streetinsider.com/Press+Releases/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html <div class="xn-content"> <p class="prntac"><i>Demonstrates a shared commitment to extend global access for the only once-daily dual-agent presbyopia-correcting eye drop in the rapidly growing presbyopia vision management segment</i></p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location> and <location value="LU/us.nj.warren" idsrc="xmltag.org" >WARREN, New Jersey</location> and <location value="LU/nl..amster" idsrc="xmltag.org" >AMSTERDAM</location> and <location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> ("Lupin") (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that <span>VISUfarma B.V.</span> ("VISUfarma"), a wholly owned subsidiary of Lupin, has entered into an exclusive licensing agreement with <span>Visus Therapeutics Inc., http://www.streetinsider.com/Press+Releases/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html Thu, 20 Aug 2026 08:00:00 -0400 500257 500257 A.06822034 A.50202117 A.50216948 LUPIN LUPIN.BO LUPIN.NS O.03319887 O.20026344 O.37382289 O.48334738 http://www.streetinsider.com/Press+Releases/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html <div class="xn-content"> <p class="prntac"><i>Demonstrates a shared commitment to extend global access for the only once-daily dual-agent presbyopia-correcting eye drop in the rapidly growing presbyopia vision management segment</i></p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location> and <location value="LU/us.nj.warren" idsrc="xmltag.org" >WARREN, New Jersey</location> and <location value="LU/nl..amster" idsrc="xmltag.org" >AMSTERDAM</location> and <location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> ("Lupin") (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that <span>VISUfarma B.V.</span> ("VISUfarma"), a wholly owned subsidiary of Lupin, has entered into an exclusive licensing agreement with <span>Visus Therapeutics Inc., http://www.streetinsider.com/Press+Releases/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html Thu, 20 Aug 2026 08:00:00 -0400 500257 500257 A.06822034 A.50202117 A.50216948 LUPIN LUPIN.BO LUPIN.NS O.03319887 O.20026344 O.37382289 O.48334738 http://www.streetinsider.com/Press+Releases/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html <div class="xn-content"> <p class="prntac"><i>Demonstrates a shared commitment to extend global access for the only once-daily dual-agent presbyopia-correcting eye drop in the rapidly growing presbyopia vision management segment</i></p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location> and <location value="LU/us.nj.warren" idsrc="xmltag.org" >WARREN, New Jersey</location> and <location value="LU/nl..amster" idsrc="xmltag.org" >AMSTERDAM</location> and <location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> ("Lupin") (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that <span>VISUfarma B.V.</span> ("VISUfarma"), a wholly owned subsidiary of Lupin, has entered into an exclusive licensing agreement with <span>Visus Therapeutics Inc., http://www.streetinsider.com/Press+Releases/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html Thu, 20 Aug 2026 08:00:00 -0400 500257 500257 A.06822034 A.50202117 A.50216948 LUPIN LUPIN.BO LUPIN.NS O.03319887 O.20026344 O.37382289 O.48334738 http://www.streetinsider.com/Press+Releases/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html <div class="xn-content"> <p class="prntac"><i>Demonstrates a shared commitment to extend global access for the only once-daily dual-agent presbyopia-correcting eye drop in the rapidly growing presbyopia vision management segment</i></p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location> and <location value="LU/us.nj.warren" idsrc="xmltag.org" >WARREN, New Jersey</location> and <location value="LU/nl..amster" idsrc="xmltag.org" >AMSTERDAM</location> and <location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> ("Lupin") (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that <span>VISUfarma B.V.</span> ("VISUfarma"), a wholly owned subsidiary of Lupin, has entered into an exclusive licensing agreement with <span>Visus Therapeutics Inc., http://www.streetinsider.com/Press+Releases/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html Thu, 20 Aug 2026 08:00:00 -0400 500257 500257 A.06822034 A.50202117 A.50216948 LUPIN LUPIN.BO LUPIN.NS O.03319887 O.20026344 O.37382289 O.48334738 http://www.streetinsider.com/Press+Releases/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html <div class="xn-content"> <p class="prntac"><i>Demonstrates a shared commitment to extend global access for the only once-daily dual-agent presbyopia-correcting eye drop in the rapidly growing presbyopia vision management segment</i></p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location> and <location value="LU/us.nj.warren" idsrc="xmltag.org" >WARREN, New Jersey</location> and <location value="LU/nl..amster" idsrc="xmltag.org" >AMSTERDAM</location> and <location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> ("Lupin") (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that <span>VISUfarma B.V.</span> ("VISUfarma"), a wholly owned subsidiary of Lupin, has entered into an exclusive licensing agreement with <span>Visus Therapeutics Inc., http://www.streetinsider.com/Press+Releases/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html Thu, 20 Aug 2026 08:00:00 -0400 500257 500257 A.06822034 A.50202117 A.50216948 LUPIN LUPIN.BO LUPIN.NS O.03319887 O.20026344 O.37382289 O.48334738 http://www.streetinsider.com/Press+Releases/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html <div class="xn-content"> <p class="prntac"><i>Demonstrates a shared commitment to extend global access for the only once-daily dual-agent presbyopia-correcting eye drop in the rapidly growing presbyopia vision management segment</i></p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location> and <location value="LU/us.nj.warren" idsrc="xmltag.org" >WARREN, New Jersey</location> and <location value="LU/nl..amster" idsrc="xmltag.org" >AMSTERDAM</location> and <location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> ("Lupin") (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that <span>VISUfarma B.V.</span> ("VISUfarma"), a wholly owned subsidiary of Lupin, has entered into an exclusive licensing agreement with <span>Visus Therapeutics Inc., http://www.streetinsider.com/Press+Releases/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html Thu, 20 Aug 2026 08:00:00 -0400 500257 500257 A.06822034 A.50202117 A.50216948 LUPIN LUPIN.BO LUPIN.NS O.03319887 O.20026344 O.37382289 O.48334738 http://www.streetinsider.com/Press+Releases/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html <div class="xn-content"> <p class="prntac"><i>Demonstrates a shared commitment to extend global access for the only once-daily dual-agent presbyopia-correcting eye drop in the rapidly growing presbyopia vision management segment</i></p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location> and <location value="LU/us.nj.warren" idsrc="xmltag.org" >WARREN, New Jersey</location> and <location value="LU/nl..amster" idsrc="xmltag.org" >AMSTERDAM</location> and <location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> ("Lupin") (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that <span>VISUfarma B.V.</span> ("VISUfarma"), a wholly owned subsidiary of Lupin, has entered into an exclusive licensing agreement with <span>Visus Therapeutics Inc., http://www.streetinsider.com/Press+Releases/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html Thu, 20 Aug 2026 08:00:00 -0400 500257 500257 A.06822034 A.50202117 A.50216948 LUPIN LUPIN.BO LUPIN.NS O.03319887 O.20026344 O.37382289 O.48334738 http://www.streetinsider.com/Press+Releases/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html <div class="xn-content"> <p class="prntac"><i>Demonstrates a shared commitment to extend global access for the only once-daily dual-agent presbyopia-correcting eye drop in the rapidly growing presbyopia vision management segment</i></p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location> and <location value="LU/us.nj.warren" idsrc="xmltag.org" >WARREN, New Jersey</location> and <location value="LU/nl..amster" idsrc="xmltag.org" >AMSTERDAM</location> and <location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> ("Lupin") (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that <span>VISUfarma B.V.</span> ("VISUfarma"), a wholly owned subsidiary of Lupin, has entered into an exclusive licensing agreement with <span>Visus Therapeutics Inc., http://www.streetinsider.com/Press+Releases/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html Thu, 20 Aug 2026 08:00:00 -0400 500257 500257 A.06822034 A.50202117 A.50216948 LUPIN LUPIN.BO LUPIN.NS O.03319887 O.20026344 O.37382289 O.48334738 http://www.streetinsider.com/Press+Releases/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html <div class="xn-content"> <p class="prntac"><i>Demonstrates a shared commitment to extend global access for the only once-daily dual-agent presbyopia-correcting eye drop in the rapidly growing presbyopia vision management segment</i></p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location> and <location value="LU/us.nj.warren" idsrc="xmltag.org" >WARREN, New Jersey</location> and <location value="LU/nl..amster" idsrc="xmltag.org" >AMSTERDAM</location> and <location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> ("Lupin") (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that <span>VISUfarma B.V.</span> ("VISUfarma"), a wholly owned subsidiary of Lupin, has entered into an exclusive licensing agreement with <span>Visus Therapeutics Inc., http://www.streetinsider.com/Press+Releases/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html Thu, 20 Aug 2026 08:00:00 -0400 500257 500257 A.06822034 A.50202117 A.50216948 LUPIN LUPIN.BO LUPIN.NS O.03319887 O.20026344 O.37382289 O.48334738 http://www.streetinsider.com/PRNewswire/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html <div class="xn-content"> <p class="prntac"><i>Demonstrates a shared commitment to extend global access for the only once-daily dual-agent presbyopia-correcting eye drop in the rapidly growing presbyopia vision management segment</i></p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location> and <location value="LU/us.nj.warren" idsrc="xmltag.org" >WARREN, New Jersey</location> and <location value="LU/nl..amster" idsrc="xmltag.org" >AMSTERDAM</location> and <location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> ("Lupin") (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that <span>VISUfarma B.V.</span> ("VISUfarma"), a wholly owned subsidiary of Lupin, has entered into an exclusive licensing agreement with <span>Visus Therapeutics Inc., http://www.streetinsider.com/PRNewswire/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html Thu, 20 Aug 2026 08:00:00 -0400 500257 500257 A.06822034 A.50202117 A.50216948 LUPIN LUPIN.BO LUPIN.NS O.03319887 O.20026344 O.37382289 O.48334738 http://www.streetinsider.com/PRNewswire/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html <div class="xn-content"> <p class="prntac"><i>Demonstrates a shared commitment to extend global access for the only once-daily dual-agent presbyopia-correcting eye drop in the rapidly growing presbyopia vision management segment</i></p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location> and <location value="LU/us.nj.warren" idsrc="xmltag.org" >WARREN, New Jersey</location> and <location value="LU/nl..amster" idsrc="xmltag.org" >AMSTERDAM</location> and <location value="LU/gb.eng.london" idsrc="xmltag.org" >LONDON</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> ("Lupin") (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that <span>VISUfarma B.V.</span> ("VISUfarma"), a wholly owned subsidiary of Lupin, has entered into an exclusive licensing agreement with <span>Visus Therapeutics Inc., http://www.streetinsider.com/PRNewswire/Lupin+and+Tenpoint+Therapeutics+Announce+Strategic+Partnership+to+Commercialize+YUVEZZI%E2%84%A2+in+the+European+Union%2C+the+United+Kingdom%2C+Switzerland%2C+Norway%2C+and+Iceland/26953155.html Thu, 20 Aug 2026 08:00:00 -0400 500257 500257 A.06822034 A.50202117 A.50216948 LUPIN LUPIN.BO LUPIN.NS O.03319887 O.20026344 O.37382289 O.48334738